FDA Approves Sotorasib with Panitumumab for KRAS G12C-mutated Colorectal Cancer By Ogkologos - February 13, 2025 574 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CodeBreaK 300 study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR 2022 ASCO Annual Meeting: A New Targeted Therapy Combination for Low-Grade Brain... June 6, 2022 Benefit Assessment of Adding Irinotecan to Capecitabine-Based Neoadjuvant Chemoradiation for Locally... November 3, 2020 EMA Recommends Granting a Marketing Authorisation for the Hybrid Medicine Imatinib July 29, 2021 What Do You Put In Your Pocket? April 28, 2021 Load more HOT NEWS Elderly Woman Seeks Trick-Or-Treaters Who Surprised Her With Gifts The Day... Efficacy and Safety of Trastuzumab Deruxtecan in Exploratory Cohorts of Patients... Blood Test for Early Detection of Cancer: Final Study Results Support... The Cancer Moonshot: A Midpoint Progress Update
